Community-based heat-sensitive moxibustion for primary hypertension: study protocol for a randomized controlled trial with patient-preference arms.

Abstract

BACKGROUND:

Low- and middle-income countries have a high prevalence of primary hypertension, but its treatment and control are often low. Heat-sensitive moxibustion (HSM), an innovative acupoint stimulation technique, may be effective for treating hypertension and thus used appropriately in primary healthcare. The objective of this study is to investigate whether HSM is effective and safe for the treatment of primary hypertension in the community.

METHODS:

This study is a multicenter, pragmatic, randomized controlled trial (RCT) with patient-preference arms. Four hundred patients with primary hypertension from seven communities will be enrolled. Initially, the communities will be randomly assigned into two study clusters, one using compulsory randomization and the other allowing treatment selection by patient preferences. Then, patients in the compulsory randomization cluster will be randomized to receive HSM plus their original antihypertensive regimen (HSM group) or only their original antihypertensive regimen (control group) for 6 months. Patients in the patient preference cluster may choose to receive HSM or control if they have a preference; otherwise, patients will be randomly assigned. The primary outcome is the change in systolic blood pressure from baseline; secondary outcomes include change in diastolic blood pressure, dosage of antihypertensive drugs, quality of life (QoL), severity of hypertensive symptoms, and incidence of cardiovascular events. Patient compliance with the HSM regimen, the cost-effectiveness ratio, and safety outcomes will also be evaluated. Outcome data will be collected at 6 monthly visits.

DISCUSSION:

This trial will provide important evidence regarding HSM as a technique for primary hypertension in primary healthcare settings. Given the randomization with patient preferences considered, the trial will also allow analyzing patient-preference effects and the comparison of randomized and nonrandomized samples, to improve the robustness and extrapolation of study conclusions.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT04788563 . Registered on March 9, 2021.

• Authors: Xu Zhou, Shuqing Li, Ling Li, Guihua Deng, Li Dai, Luyu Chai, Qingni Wu, Ziqian Yao, Minchao Deng, Weifeng Zhu, Yong Fu, Xin Sun
• Journal: Trials (Trials) Vol. 23 Issue 1 Pg. 154 (Feb 16 2022) ISSN: 1745-6215 [Electronic] England
• PMID: 35172871 (Publication Type: Clinical Trial Protocol, Journal Article)
• Copyright: © 2022. The Author(s).

Chemical References

• Antihypertensive Agents

Topics

• Antihypertensive Agents (therapeutic use)
• Hot Temperature
• Humans
• Hypertension (drug therapy, therapy)
• Moxibustion (adverse effects)
• Multicenter Studies as Topic
• Patient Preference
• Randomized Controlled Trials as Topic
• Treatment Outcome